feedback

Course Director

Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS

Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Faculty

Arjun Balar
Arjun Balar, MD

Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

Noah M. Hahn
Noah M. Hahn, MD

Johns Hopkins Greenberg
Bladder Cancer Institute
Baltimore, Maryland

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2019-Jun-06
Expiration Date:2020-Jun-05
Estimated Time for Completion:1.5 hours
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

The therapeutic landscape of advanced urothelial carcinoma of the bladder has undergone significant transformation in the last 2 years, with the emergence of immune checkpoint inhibitors as an essential component of the treatment armamentarium. Extensive research is also focused on newer approaches, such as antibody-drug conjugates and FGFR inhibitors, against actionable targets on urothelial cancer cells. This rapid expansion in the field poses several challenges for urologists and other healthcare professionals who are essential to the multidisciplinary team managing patients with urothelial cancer.

In this PeerView activity, based on a recent live symposium, a panel of bladder cancer experts review the science and latest evidence on immunotherapeutic and targeted strategies for urothelial cancers combined with practical, interactive segments offering the urologist’s perspective on achieving optimal outcomes through appropriate counseling of patients and effective collaboration among different specialists, including urologists and oncologists.

Upon completion of this activity, participants should be better able to:
  • Describe the rationale for and mechanisms of action of novel immunotherapeutic and targeted strategies in clinical development for management of urothelial cancer
  • Discuss the latest evidence on and clinical roles of approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors throughout the urothelial cancer disease continuum
  • Employ effective strategies to ensure optimal and timely application of the latest treatment approaches for patients with urothelial cancer, including in the context of clinical trial enrollment
  • Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with novel therapies for urothelial cancer

Target Audience

This activity has been designed to meet the educational needs of urologists, oncologists, nurse practitioners, physician assistants, and other clinicians involved in the management of urothelial cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 6, 2019 - June 5, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director

Neal D. Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; Color Genomics; Dendreon Pharmaceuticals LLC; Ferring Pharmaceuticals; F. Hoffmann-La Roche/Genentech, Inc.; Genomic Health; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Myriad Genetics; Nymox Pharmaceutical Corporation; Pfizer Inc.; Sanofi Genzyme; and Tolmar Pharmaceuticals, Inc.

Faculty

Arjun Balar, MD
Associate Professor of Medicine
Director – Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

Arjun Balar, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Seattle Genetics, Inc.
Grant/Research Support from AstraZenca; Genentech, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc.

Noah M. Hahn, MD
Associate Professor of Oncology and Urology
Deputy Director, Johns Hopkins Greenberg Bladder Cancer Institute
Director, Medical Oncology Bladder Cancer Program
Baltimore, Maryland

Noah M. Hahn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol-Myers Squibb; Champions Oncology; Ciclomed; Ferring Pharmaceuticals; Genentech, Inc.; Health Advances; Inovio Pharmaceuticals; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pieris Pharmaceuticals; Principia Biopharma Inc.; Rexahn Pharmaceuticals Inc.; Seattle Genetics; TARIS BioMedical, Inc.; and TransMed.
Grant/Research Support from Astex Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; Pieris Pharmaceuticals; Principia Biopharma Inc.; and Seattle Genetics.
Honorarium from Bladder Cancer Academy.

Medical Director

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6486-19-T.

Providership


This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through educational grants from Astellas and Seattle Genetics, Bristol-Myers Squibb, Genentech, Incyte Corporation, and Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.